Lineage Cell Therapeutics (LCTX) Net Income Growth (5y) (2015 - 2026)
Lineage Cell Therapeutics (LCTX) Net Income Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.62 Bn | 466.83 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn |
| 10 | Lineage Cell Therapeutics | 253.61 Mn | 190.89 Mn | 1.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -67.91% |
| Dec 31, 2025 | -51.25% |
| Sep 30, 2025 | -18.84% |
| Jun 30, 2025 | -28.11% |
| Mar 31, 2025 | 4.17% |
| Dec 31, 2024 | -18.89% |
| Sep 30, 2024 | 30.50% |
| Jun 30, 2024 | 29.23% |
| Mar 31, 2024 | -17.24% |
| Dec 31, 2023 | 36.41% |
| Sep 30, 2023 | -16.08% |
| Jun 30, 2023 | -2.29% |
| Mar 31, 2023 | 41.39% |
| Dec 31, 2022 | 39.32% |
| Sep 30, 2022 | -18.37% |
| Jun 30, 2022 | 15.88% |
| Mar 31, 2022 | -16.43% |
| Dec 31, 2021 | -29.33% |
| Sep 30, 2021 | -17.79% |
| Jun 30, 2021 | -17.44% |